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Summary 
Human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins (gp120 and gp41) elicit 
virus-neutralizing antibodies (VNAB) and also antibodies enhancing HIV-1 infection (EAB). 
Several epitopes eliciting VNAB have been defined, the principal virus-neutralizing determinant 
being assigned to the V3 loop of gp120. To provide a background for a rational design of anti- 
HIV vaccines, it also appears important to define domains eliciting EAB. This was accomplished 
by screening antisera against synthetic peptides covering almost the entire sequence of gp120/gp41 
for their enhancing effects on HIV-1 infection of MT-2 cells, a continuous T  cell line.  Many 
(16/30) of the antisera  significantly enhanced HIV-1  in the presence of human complement. 
Antibodies to complement receptor type 2 (CK2) abrogated the antibody-mediated enhancement 
of HIV-1 infection. Antisera to V3 hypervariable  loops of 21 distinct HIV-1 isolates were also 
tested for their enhancing effects on HIV-11.B infection. 11 of these sera contained VNAB and 
10 enhanced HIV-lmB infection. All antisera with virus-enhancing activity contained antibodies 
crossreactive with the V3 loop of HIV-lmB,  and the virus-enhancing activity increased with 
increasing serological  crossreactivity.  These results suggest that immunization with antigens 
encompassing V3 loops may elicit  EAB rather than protective antibodies if epitopes on the 
immunogen and the predominant HIV-1 isolate infecting a population are insufficiently matched, 
i.e.,  crossreactive  serologically  but not at the level of virus neutralization. 
I 
t was reported that antibodies mediating enhancement of 
￿9  HIV-1 infection (enhancing antibodies [EAB] 1) could be 
detected in sera of most HIV-infected individuals (1, 2) and 
that the occurrence of EAB correlated with severity of dis- 
ease (3, 4). EAB were detected not only in human sera (1-5), 
but also in sera of HIV-infected chimpanzees (6, 7), of simian 
immunodeficiency  virus (SIV)-infected rhesus macaques (8), 
and of guinea pigs immunized with HIV (7). Recently, it 
was found that some human mAbs also contained EAB (9, 
10). However, the epitope specificity of EAB has not been sys- 
tematically investigated. 
The HIV-1 envelope glycoprotein gp160 (gp120 and gp41) 
contains a number of immunodominant  epitopes eliciting both 
antibody- and cell-mediated immune responses that may con- 
tribute to protection against HIV-1 infection and/or to delay 
of disease symptoms after infection (11-22). Therefore, gp160 
has been selected as the first candidate HIV-1 subunit vaccine 
for phase I trials in healthy volunteers (23) and in patients 
t Abbreviations used in this paper: EAB, enhancing antibodies; HS, human 
sera; SIV, simian immunodeficiency virus; TCID,  50%  tissue culture 
infective dose. 
with early HIV-1 infection (24). The conclusion was reached 
that gp160 was safe and immunogenic, eliciting both humoral 
and cellular immunity to gp120/gp41. However, it was also 
noticed that some sera from healthy subjects immunized with 
gp160 contained antibodies not neutralizing but rather en- 
hancing HIV-1 infection (23), suggesting that some epitopes 
on gp160 may elicit virus-neutralizing antibodies while others 
may elicit EAB. Epitopes on gp160 eliciting virus-neutralizing 
antibodies have been extensively  studied (11-19), but there 
are only a few reports concerning epitopes that may elicit 
EAB (9,  10). In the present study rabbit antisera  directed 
against: (a) 30 synthetic peptides from the sequence of HIV- 
IIIIB gp160 and (b) V3 hypervariable  loops of 21  distinct 
HW-1 isolates were tested for their enhancing effects on HIV-1 
infection. 
Materials and Methods 
Cells and  Virus.  T-lymphoblastoid MT-2 and H9 cells were 
grown in RPMI 1640 (Gibco Laboratories, Grand Island, NY) with 
10% heat-inactivated  FCS (Gibco Laboratories) and 100 U of peni- 
cillin and 100 #g/ml streptomycin (Gibco Laboratories). HIV-11nB 
was grown in H9 and MT-2 cells. Virus was obtained from pro- 
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by filtration through a 0.45-/zm filter (Nalgene Co., Rochester, 
NY).  The infectivity of HIV-lmB was titrated using MT-2 cells 
under conditions described by Johnson and Byington (25). The 
titers of virus stocks were 104 to 106 50% tissue culture infective 
doses (TCIDs0). 
Antisera, Normal Sera, and mAh  Rabbit antisera to synthetic 
peptides were prepared as previously  described (17). Briefly,  30 pep- 
tides covering almost the entire sequence of HIV-1/Im gp120 and 
gp41, and 21 peptides corresponding to full-length V3 hypervari- 
able loops of distinct HIV-1 isolates, were synthesized and purified 
(17, 18). Two NZW rabbits were immunized with 200/~g of the 
respective peptides in combination with CFA. Before immuniza- 
tion, the V3 loop peptides were oxidized by exposure to air in PBS 
overnight to allow the formation of disulfide bonds between the 
NH2- and COOH-terminal  cysteines. The rabbits were boosted 
with 200-#g doses of  peptides in combination with IFA in biweekly 
intervals. 2 wk after each immunization, blood samples were taken 
and analyzed for antibodies by RIA. 10 wk after the initial immu- 
nization, the rabbits were killed after collecting blood by cardiac 
puncture. Before use, all the antisera were inactivated at 56~  for 
30 rain to destroy complement. Residual cytotoxicity of some an- 
tisera after the heat treatment was eliminated by adsorbing them 
on MT-2 cells (107 cells for 1 ml serum) at 4~  for 1 h. Human 
sera (HS) were collected from healthy individuals,  pooled, and kept 
at  -70~  until use. The complement activities in this batch of 
HS have been determined previously (26, 27). Anticomplement 
receptor type 2 (CR2, CD21) mAb (OKB7) was purchased from 
Ortho Diagnostic Systems Inc. (Raritan, NJ). 
Double-antibody Radioimmunoassays.  The level of antipeptide an- 
tibodies in rabbit antisera  was determined by double-antibody  RIA 
as described previously (17, 18). In brief, wells of 96-well polysty- 
rene plates (Immulon II; Dynatech Laboratories, Inc., ChantiUy, 
VA) were coated with the respective synthetic peptides (200 #1; 
20/zg/ml in 0.1 M Tris, pH 8.8) overnight at 20~  and post- 
coated with BSA and gelatin (10 and 2.5 mg/ml, respectively).  Seri- 
ally diluted antipeptide antisera  were added to the wells. After over- 
night incubation at 25~  the quantity of  attached rabbit IgG was 
determined  from  subsequent attachment  of  ~zSI-labeled goat 
anti-rabbit IgG. Dilution endpoints were calculated as described 
by Ritchie et al. (28). 
Titration of HIV-1 Infectivity in MT-2 Cells.  HIV-1  infectivity  was 
determined by two distinct methods, an ELISA measuring HIV-1 
core protein P24 production and a colorimetric assay for HIV- 
mediated cytopathogenesis, as described previously (29). Briefly, 
104 MT-2 cells in 96-well plates were infected with dilutions of 
HIV-lmB in 200/xl RPMI 1640 with 10% FCS. After 1 and 24 h, 
half of the culture medium was changed. On the fourth day after 
incubation at 37~  100 #1 of culture supematant was collected 
from each well and an equal volume of fresh medium was added 
to the wells. The collected supernatants were mixed with equal 
volumes of 5% Triton X-100 and assayed  for P24 using a kit from 
Coulter Immunology (Hialeah, FL). On the sixth day after infec- 
tion, an indicator XTT tetrazolium dye (1 mg/ml; 50 #l/well; Poly- 
Sciencies, Inc., Warrington, PA) was added to the cells. After 4 
h, intracellular formazan was determined colorimetrically at 450 
nm. The percentage of cytotopathogenesis was calculated using 
the  following formula:  100x [(OD4s0 in  negative control  - 
OD4s0 in experiment)/(OD450 in negative control  -  OD450  in 
positive control)]. The negative  control corresponded to cells mixed 
with culture medium, instead of HIV, while the positive control 
represented cells mixed with 100 TCIDs0 HIV-I,tB, which lysed 
100% of the MT-2 cells. 
Determination of Antibody-mediated Enhancement of 141I/:-1 Infec- 
tion.  Antisera  were serially  diluted in RPMI 1640 containing 10% 
FCS. Aliquots of the diluted antisera were added to wells of 96- 
well plates and mixed with an equal volume of HS (final dilution 
1:50) and 25 /~1 of HIV-lm (45 TCIDs0). After incubation at 
37~  for 1 h, 104 MT-2 cells were added to this mixture. The in- 
fectivity of HIV-1 was subsequently  determined as described above. 
The percentages of enhancement of P24 production and of cyto- 
pathogenesis were calculated using the following formula: 100x 
[(E  -  C)/C]. E represents the amount of P24 (ng/ml) and the 
percent ofcytopathogenesis,  respectively,  in the presence of antisera, 
and C represents those in the absence of antisera. 
Blocking Complement Receptor Type 2 (CR2) with mAh  MT-2 
cells (4  x  10  s) were pretreated with 25/zg of OKB7 mAb at 
37~  for 1 h and washed twice in RPMI 1640. The cells were 
resuspended in culture medium and placed in 96-well plates. HIV- 
1rob (45 TCIDs0), 1:20 diluted rabbit antisera directed against the 
V3 loop of HIV-1-NY-5 (which was shown to contain EAB in pre- 
liminary experiments), and HS (1:50 diluted in RPMI 1640) were 
added to MT-2 cells. The cells  were subsequently  infected  with HIV. 
Untreated infected cells were used as controls. Virus enhancement 
was calculated as described above. 
Results 
Enhancement of HIV1ma Infection by Rabbit Antisera Directed 
Against Synthetic Peptides  from HIV-l um gp120/gp41.  Rabbit 
antisera directed against 30 synthetic peptides from gp120 
and gp41 were screened for their enhancing activity on HIV-1 
infection of MT-2  cells. Without adding HS,  none of the 
antisera  significantly enhanced  either  P24  production  or 
cytopathogenesis  mediated by  HIV-1  infection (data  not 
shown).  However, after adding HS,  16 of the 30 antisera 
significantly enhanced (>100%) P24 production (Fig.  1 A) 
and 15 antisera  markedly (>60%) enhanced HIV-mediated 
cytopathogenesis (1 B). Although the enhancement of P24 
production by these antisera is higher than that of cytopatho- 
genesis,  both are closely correlated (r  =  0.869).  Epitopes 
eliciting the highest levels of EAB appeared clustered mainly 
in  regions  located NH2  terminally from  the  V3  loop  of 
gp120  and  on  segments  of  gp41.  The  only  antiserum 
significantly inhibiting virus replication was that directed 
against the V3 loop peptide. 
Enhancement of HIV-1 infection mediated by the rabbit 
antisera is dose dependent (Fig. 2), decreasing gradually with 
increased  antiserum dilution from 1:10 to 1:106  . 
Enhancement of HIVlm  Infection by Rabbit Antisera to Syn- 
thetic Peptides  from V3 Hypervariable Loops of 21 Distinct 1-1II/--1 
Isolates.  21 rabbit antisera directed against V3 hypervariable 
loops of gp120 from distinct HIV-1 isolates were also tested 
for their enhancing effects on HIV-lm infection. The results 
are shown in Fig. 3. In the presence of HS, 11 antisera neu- 
tralized the infectivity of HIV-lnm at least partially, while 
10 antisera enhanced P24  production. Similar results were 
obtained by measuring HIV-mediated cytopathogenesis (data 
not shown). Antisera to peptides most closely related im- 
munologically to the BH10 V3 peptide (18) neutralized the 
infectivity of HIV-lnm. Interestingly, the enhancement of 
HIV-1 infection mediated by the 10 non-neutralizing antisera 
was correlated with their less-close crossreactivity with the 
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Figure  1.  Enhancement  of HIV-I.IB infection  by  rabbit  antibodies 
directed  against  synthetic peptides  from gp120/gp41  of HIV-I,m.  En- 
hancement (or inhibition) was measured by production of P24 gag an- 
tigen (.4) or by HIV-mediated cytopathogenesis (B) (see Materials and 
Methods). Positive results represent enhancement, while negative results 
indicate inhibition  (i.e., virus neutralization).  (WT~) Peptide corresponding 
to the V3 loop;  (~)  all other peptides. 
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V3 loop peptide of HIV-lmB as detected by RIA (18)(Fig. 
4).  These  results  suggest  that  subtype-specific  antibodies 
directed against V3 loops, if not sufficiently  matched with 
the HIV-1  strains used for infection of cells, may not neu- 
tralize but rather enhance HIV-1  infection and that higher 
titers of non-neutralizing antibodies may result in higher en- 
hancing activity. 
Heat Treatment  of  HS Decreases  Enhancement  of  EAB-mediated 
HIV1 Infection.  It was reported  that  human complement 
was involved in human, chimpanzee, and rhesus macaque EAB- 
mediated enhancement of HIV and SIV infection, respectively, 
via CR2 (2, 4, 6, 8, 30, 31),  and that human complement 
could directly  enhance HIV-1  infection via  the alternative 
pathway (32, 33). In this study, it was found that rabbit an- 
tisera enhanced  HIV-1  infection of MT-2  cells  only in the 
presence of HS. To establish whether or not human comple- 
Figure 3.  Effect of rabbit antisera directed against V3 hypervariable loop 
peptides from 21 distinct HIV-1 isolates on replication of HIV-lm. Rabbit 
antisera directed against synthetic peptides from HIV-1 isolates, indicated 
on the abscissa, were tested for enhancement or inhibition of HIV-I.m 
infection of MT-2 cells in the presence of HS.  Experimental  conditions 
and calculations  are the same as for Fig.  1. 
ment is the essential factor in normal HS required by rabbit 
EAB for enhancing HIV-1 infection, HS was incubated at 
56~  for 30 min and used in virus-enhancing assays. Without 
adding EAB (rabbit antiserum against the V3 loop peptide 
from HIV-1 isolate NY-5, a preselected HIV-l-enhancing an- 
tiserum), HS itself could significantly enhance P24 produc- 
tion (>100%) (Fig. 5). However, when heated HS was added 
to the virus, no significant enhancement could be observed, 
suggesting that human complement itself is able to enhance 
HIV-1 infection, probably via the alternative pathway, as sug- 
1559  Jiang  et al. ~)  140- 
m 
D 
0 
5 
g 
(.) 
z 
T 
Z 
U 
N 
120. 
100. 
80. 
60 
40 
20 
0 
10 
| 
|  @ 
I  I  I 
1  O0  1,000  10,000  100 
RECIPROCAL OF ANTIBODY DILUTION ENDPOINT 
DO0 
Figure 4.  Correhtion between enhancement of HIV-11rm  replication by 
rabbit antisera directed against V3 peptides from distinct HIV-1 isolates 
and the reactivities of these antisera with the BH10 V3 peptide. Ordinate, 
percentage of enhancement of P24 production mediated by rabbit antisera 
directed against synthetic peptides from V3 loops of HIV-1 isolates: 1, 
Z-3; 2, ELI; 3, Z-6; 4, JY-1; 5, WMJ-2; 6, Z-321; 7, CD451; 8, LAV-MA; 
9, NY-5; 10, WMJ-1. Abscissa, reciprocal dilution endpoints of the an- 
tisera as measured by RIA using wells coated with the BH10 V3 peptide 
(results from reference 18). 
gested by Boyer et al. (32). When EAB and HS were added 
to the virus at the same time, P24 production was further 
increased ("~400%).  This increase was not observed when 
heated HS, instead of untreated HS, was added. These results 
suggest that rabbit EAB-mediated HIV-1 infection of MT-2 
cells is dependent on the presence of human complement. 
Complement-dependent Rabbit EAB-raediated Enhancement of 
HIV-1 Infection of  MT-2 Cells Is Blocked by Anti-CR2 rnAt~  It 
was reported that CR2 played an important role in comple- 
ment-dependent human EAB-mediated enhancement of HIV-1 
infection (2, 4, 30-32,  34). MT-2 ceUs express a high level 
of CR2 (2), which were effectively blocked by an anti-CR2 
mouse mAb OKB7 (34). To determine whether or not CR2 
plays a role in rabbit EAB-mediated, human complement-de- 
pendent enhancement of HIV-1 infection of MT-2 cells, the 
effect of  mouse anti-CR2 mAb, OKB7, on enhancement  was 
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Figure 6.  Anti-CR2 mAb blocking of complement-dependent,  rabbit 
EAB-mediated enhancement of HIV-1 infection of MT-2 cells. MT-2 cells 
were treated with OKB7 (anti-CR2 mAb) or untreated before they were 
mixed with HS, rabbit EAB, and HIV-lmB for virus-enhancing assays. 
studied. As shown in Fig. 6, P24 production by HIV-l-infected 
OKB7-treated and untreated MT-2 cells did not differ sig- 
nificantly when human complement and rabbit EAB were 
not added. When human complement, but no rabbit EAB, 
was added to HIV-1, P24 production in OKB7-treated MT-2 
cells was lower than that in untreated MT-2 cells, confirming 
that human complement-mediated enhancement of HIV-1 
infection occurred, and was partially blocked by anti-CR2 
antibody. With untreated MT-2 cells and rabbit EAB, human 
complement significantly  increased  P24 production, as already 
shown in Fig. 5. However, when MT-2 cells were pretreated 
with OBK7 mAb, the enhancement of P24 production by 
human complement and rabbit EAB was abolished. These 
results suggest that human CR2 indeed plays an important 
role in rabbit EAB-mediated, human complement-dependent 
enhancement of HIV-1 infection. 
Discussion 
The following major conclusions emanate from the results 
presented here: (a) antisera to several peptides from HIV-1 
gp120/gp41 enhance HIV-1 infection,  suggesting  the pres- 
ence of a mosaic of contiguous epitopes on the virion surface 
and that attachment of antibodies to many, if not all, of these 
epitopes fadlitates HIV-infection; (b) EAB-mediated enhance- 
ment of HIV-1 infection of MT-2 cells is dependent on human 
complement and CR2; (c) V3 hypervariable loops from one 
HIV-1 isolate may dicit antibodies enhancing infection by 
another HIV-1 isolate. 
It has been well established that sera from HIV-l-infected 
humans (1-5) and chimpanzees  (6, 7), from SIV-infected  rhesus 
macaques (8), and from HIV-immunized guinea pigs (7) con- 
tain antibodies that could enhance HIV-1 or SIV infections. 
For the design of immunogens for vaccination against HIV-1, 
it seems important to establish the epitope specificity  of  EAB. 
The availability in our laboratory of a multitude of antisera 
to peptides from gp120/gp41 (17, 18) offered an opportunity 
to accomplish this by screening these sera for EAB. It was 
found that many epitopes on gp120/gp41  can elicit EAB. 
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bound to an immunodominant region in gp41 (amino acid 
residues 586-620), enhanced HIV-1 infection. Enhancement 
mediated by these two mAbs and by human polyclonal an- 
tisera  to HIV-1  could be blocked by the synthetic peptide 
(586-620). More recently, Robinson et al. (10) reported an- 
other four human mAbs with HIV-l-enhancing activity, three 
of which recognized the same peptide and one of which rec- 
ognized a peptide (651-670;  numbering system as in refer- 
ences 9 and 17) from gp41. They concluded that these two 
domains on gp41 could stimulate the in vivo formation of 
EAB  and  that  there  are  only  a  few  epitopes on  HIV-1 
gp120/gp41 that could stimulate the production of EAB. Our 
results confirmed that these two regions in gp41 elicit EAB 
(Fig. 1). However, our results indicate that many other regions 
in gp120/gp41 are involved in apparent virus infectivity en- 
hancement after binding antibodies. Regions of gp120/gp41 
involved in binding of antipeptide EAB appear to be exposed 
on the surface ofvirions (our unpublished data), as one would 
expect. Therefore, it seems possible that any antibodies binding 
complement and attaching to the surface of HIV-1 particles 
will function as EAB, unless they are virus neutralizing. This 
conclusion is supported by the enhancing activity of some 
antibodies directed against HIV-1 gp120 V3 loop (Fig. 3, see 
below). The discrepancy between these conclusions and the 
findings of Robinson et al.  (9,  10) is apparent rather than 
factual for the following reasons: the region (579-611) of gp41 
is immunodominant and antibodies against this domain are 
the most prevalent in individuals infected with HIV-1 (24, 
35-37). Therefore, B lymphocyte clones that produce mAb 
against the aforementioned domain and having enhancing 
activity on HIV-infection would be preferentially selected from 
peripheral B cells of HIV-l-infected individuals. It is also not 
surprising that most of EAB were removed from human anti- 
HIV-1  sera by adsorption on a synthetic peptide from this 
immunodominant region (9,  10). 
The V3 hypervariable loop of gp120 encompasses the prin- 
cipal neutralizing determinant (18, 38-40)  and is involved 
in the process of virion-cell membrane fusion (41, 42). Be- 
cause of the biologically important role of the V3 loop in 
the life cycle of HIV-1, the peptide from this region may be 
considered as a candidate component for a vaccine against 
HIV-1 infection. Indeed, antibodies to the V3 loop rendered 
HIV-1HIB virions noninfectious for chimpanzees (43).  Re- 
cently, it was demonstrated that high levels of virus-neu- 
tralizing antibodies were elicited by boosting chimpanzees 
with synthetic peptides from the V3 loop after priming with 
gp160 and that the antibodies were protective against HIV-1 
challenge (44,  45).  Neutralizing antibodies elicited by the 
V3 loop are HIV-1 subtype (isolate) specific (39,  40),  sug- 
gesting the need to incorporate a multitude of V3 loop pep- 
tides into a vaccine expected to be broadly effective (18). The 
serological crossreactivity,  as measured by ILIA, between V3 
loops of distinct HIV-1 isolates is related to the extent of their 
amino acid sequence homology (18). However, the impact 
of serological crossreactivity on biological properties of anti- 
V3 loop antisera, i.e., virus neutralization or enhancement, 
has not been systematically investigated before. Results pre- 
sented here show that V3 hypervariable loops from one HIV-1 
isolate may elicit antibodies enhancing infection by another 
HIV-1 isolate and that the enhancement mediated by the an- 
tibodies, if they had no neutralizing effect on the HIV-1 iso- 
late tested, correlated with serological crossreactivity. There- 
fore, immunization with HIV-1 antigens encompassing the 
V3 loop or with synthetic peptides from the V3 loop may 
be potentially harmful rather than protective if epitopes on 
the immunogen and the predominant HIV-1 isolate infecting 
a population are insufficiently matched, i.e., crossreactive sero- 
logically but not at the level of virus neutralization. 
The generation in vivo of HIV-1 escape mutants that cannot 
be neutralized by anti-V3 loop-specific antibodies generated 
in the course of infection has been well documented (46, 47). 
Considering our results, it seems possible that these antibodies 
may have an enhancing  effect on the replication of the emerging 
variant(s) and may thus contribute to persistence and patho- 
genesis of the infection. 
It has been established that human complement and CR2 
play important roles in human EAB-mediated enhancement 
of HIV-1 infection of CD4 + T lymphocytes (2, 8, 30, 31). 
Our results demonstrated that rabbit EAB also require human 
complement to enhance HIV-1 infection. CR2 is also critical 
in the rabbit EAB-mediated, complement-dependent  enhance- 
ment of HIV-1 infection, since this type of enhancement of 
HIV-1 infection could be blocked by anti-CR2 antibody. Most 
antibodies directed against synthetic peptides from the se- 
quence of HIV-1 gp120/gp41 bind onto the surface of HIV-1 
virions (our unpublished data). If the respective epitopes are 
located on functional regions critical for virus replication and 
transmission, the bound antibodies may neutralize HIV-1. 
If not, the virion-antibody complexes may activate comple- 
ment and via CR2 enter the target cells, resulting in enhance- 
ment of HIV-1 infection. Thus, any antibodies specific for 
epitopes on gp120/gp41, if not protective, may have virus- 
enhancing effects and be potentially harmful. How to mini- 
mize the generation of potentially harmful antibodies and 
to maximize the production of protective antibodies is a crit- 
ical question in designing vaccines against HIV-1. 
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